Journal for immunotherapy of cancer
-
J Immunother Cancer · Nov 2019
Multicenter StudyCombined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.
Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently unclear. ⋯ The tolerability of the combined checkpoint blockade in UM may possibly be better than in trials on cutaneous melanoma. This study implies that combined checkpoint blockade represents the hitherto most effective treatment option available for metastatic UM available outside of clinical trials.